In this startup showcase, we explore the innovative work of Accunea, a London-based medical device business that is developing a game-changing technology for monitoring transplant organ function in real-time. With their premiere product, RenoSure, Accunea aims to improve the success rate of kidney transplant procedures and transform the way doctors and clinicians approach postoperative care. Read on to learn more about this exciting startup and their mission to save lives.
Introducing Accunea: A Medical Device Business with a Vision
Founded by Jez Marston, Nick Housby, and Dr. Robert Learney, three professionals with extensive experience in medical device development and commercialization, Accunea is a startup with a clear mission: to revolutionize the field of transplant medicine with advanced monitoring technologies. The company’s flagship product, RenoSure, is a portable, point-of-care device that provides accurate and continuous monitoring of kidney function and metabolic condition. With this device, doctors and clinicians can detect early signs of complications and make real-time adjustments in treatment to improve patient outcomes.
RenoSure: A Game-Changing Technology
RenoSure is a patent-pending technology that was initially developed by Dr. Learney during his PhD research at Imperial College London. The technology uses a combination of biosensors and microfluidics to detect changes in the levels of key biomarkers in a patient’s blood. By analyzing these biomarkers, RenoSure can provide accurate and real-time measurements of kidney function and metabolic condition, allowing doctors to detect early signs of complications and adjust treatment accordingly. Unlike traditional monitoring systems, RenoSure is non-invasive, portable, and can be used at the bedside, making it an ideal tool for clinical centers.
The Potential Impact of RenoSure
Kidney transplantation is the only cure for dialysis-dependent renal failure, and each transplant can save a life and save money for healthcare systems. However, the success rate of kidney transplants is heavily dependent on the function of the organ being implanted, which is often unknown until after surgery. With RenoSure, doctors and clinicians can monitor the function of the transplanted kidney in real-time, detect early signs of complications, and adjust treatment accordingly. This can greatly improve the success rate of kidney transplants and increase the number of lives saved.
Fundraising and Future Plans
Accunea Ltd. is currently raising funds to take the RenoSure device forward into pre-clinical trials. The company has already received support from various investors and organizations, including Innovate UK, the UK’s innovation agency. Accunea’s ultimate goal is to bring their innovative technology to clinical centers worldwide and transform the way doctors and clinicians approach transplant medicine.
Accunea is a startup with a clear mission and a game-changing technology. With their RenoSure device, the company aims to improve the success rate of kidney transplant procedures and transform the way doctors and clinicians approach postoperative care. We look forward to following Accunea’s progress and seeing the impact that their innovative technology will have on the field of transplant medicine.
Want to supercharge your brand’s visibility within the UK tech industry? Reach startup founders, investors, and C-level executives with sponsored articles on UKT.news. Connect with us and discover how our advertising solutions can propel your brand to new heights. Explore our Sponsored Articles & Partnerships Program here.